Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma

STAMFORD, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
February 24, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

– Topline Analysis from Phase 3 DeFi Trial Expected to be Triggered in the First Quarter of 2022; Topline Data Expected to be Reported During the First Half of 2022 – – Expanded Collaboration with...
February 01, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
January 04, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
December 10, 2021 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

– Seventh Clinical Collaboration Represents Continued Execution on Strategy to Advance Nirogacestat in Combination with BCMA Therapies – STAMFORD, Conn., Dec. 10, 2021 (GLOBE NEWSWIRE) --...
December 06, 2021 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

STAMFORD, Conn., Dec. 06, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
November 29, 2021 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

STAMFORD, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
November 23, 2021 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
November 04, 2021 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

– Announced Advancement into Randomized Phase 2 Expansion and Addition of New Sub-studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in...
October 27, 2021 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma

-- Based on Encouraging Preliminary Data Observed with the First Dose Exploration Cohort (0.95 mg/kg BLENREP Q3W + Nirogacestat) a Randomized Phase 2 Cohort Expansion to Compare Against 2.5 mg/kg Q3W...